| The consensus molecular subtypes of colorectal cancer J Guinney, R Dienstmann, X Wang, A De Reynies, A Schlicker, ... Nature medicine 21 (11), 1350-1356, 2015 | 5071 | 2015 |
| Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors D Dangaj, M Bruand, AJ Grimm, C Ronet, D Barras, PA Duttagupta, ... Cancer cell 35 (6), 885-900. e10, 2019 | 670 | 2019 |
| Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy FG Herrera, C Ronet, M Ochoa de Olza, D Barras, I Crespo, M Andreatta, ... Cancer discovery 12 (1), 108-133, 2022 | 268 | 2022 |
| BRAF V600E mutant colorectal cancer subtypes based on gene expression D Barras, E Missiaglia, P Wirapati, OM Sieber, RN Jorissen, C Love, ... Clinical Cancer Research 23 (1), 104-115, 2017 | 234 | 2017 |
| BRAF Mutation in Colorectal Cancer: An Update: Supplementary Issue: Biomarkers for Colon Cancer D Barras Biomarkers in cancer 7, BIC. S25248, 2015 | 220 | 2015 |
| High antigen levels induce an exhausted phenotype in a chronic infection without impairing T cell expansion and survival DT Utzschneider, F Alfei, P Roelli, D Barras, V Chennupati, S Darbre, ... Journal of Experimental Medicine 213 (9), 1819-1834, 2016 | 186 | 2016 |
| Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching L De Smedt, S Palmans, D Andel, O Govaere, B Boeckx, D Smeets, ... British journal of cancer 116 (1), 58-65, 2017 | 173 | 2017 |
| Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation J Duraiswamy, R Turrini, A Minasyan, D Barras, I Crespo, AJ Grimm, ... Cancer cell 39 (12), 1623-1642. e20, 2021 | 127 | 2021 |
| Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer Q Lan, S Peyvandi, N Duffey, YT Huang, D Barras, W Held, F Richard, ... Oncogene 38 (15), 2814-2829, 2019 | 117 | 2019 |
| Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING M Bruand, D Barras, M Mina, E Ghisoni, M Morotti, E Lanitis, N Fahr, ... Cell reports 36 (3), 2021 | 100 | 2021 |
| Promises of apoptosis-inducing peptides in cancer therapeutics D Barras, C Widmann Current pharmaceutical biotechnology 12 (8), 1153-1165, 2011 | 70 | 2011 |
| Aldehyde dehydrogenase activity plays a Key role in the aggressive phenotype of neuroblastoma M Flahaut, N Jauquier, N Chevalier, K Nardou, K Balmas Bourloud, ... BMC cancer 16, 1-13, 2016 | 68 | 2016 |
| BCL9/9L-β-catenin signaling is associated with poor outcome in colorectal cancer AE Moor, P Anderle, C Cantù, P Rodriguez, N Wiedemann, F Baruthio, ... EBioMedicine 2 (12), 1932-1943, 2015 | 67 | 2015 |
| PGE2 inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function M Morotti, AJ Grimm, HC Hope, M Arnaud, M Desbuisson, N Rayroux, ... Nature, 1-9, 2024 | 54 | 2024 |
| Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice S Ragusa, B Prat-Luri, A González-Loyola, S Nassiri, ML Squadrito, ... The Journal of clinical investigation 130 (3), 1199-1216, 2020 | 54 | 2020 |
| The transcription factor Rfx7 limits metabolism of NK cells and promotes their maintenance and immunity W Castro, ST Chelbi, C Niogret, C Ramon-Barros, SPM Welten, ... Nature immunology 19 (8), 809-820, 2018 | 54 | 2018 |
| Fragment N2, a caspase‐3‐generated RasGAP fragment, inhibits breast cancer metastatic progression D Barras, G Lorusso, B Lhermitte, D Viertl, C Rüegg, C Widmann International journal of cancer 135 (1), 242-247, 2014 | 41 | 2014 |
| Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors J Schmidt, J Chiffelle, MAS Perez, M Magnin, S Bobisse, M Arnaud, ... Nature communications 14 (1), 3188, 2023 | 39 | 2023 |
| GAP-independent functions of DLC1 in metastasis D Barras, C Widmann Cancer and Metastasis Reviews 33, 87-100, 2014 | 39 | 2014 |
| The interleukin 22 pathway interacts with mutant KRAS to promote poor prognosis in colon cancer S McCuaig, D Barras, EH Mann, M Friedrich, SJ Bullers, A Janney, ... Clinical Cancer Research 26 (16), 4313-4325, 2020 | 35 | 2020 |
